Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 12/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 12/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409485 | 0.88 | CREBBP (0.57) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL407222 | 0.85 | CREBBP (0.61) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL407556 | 0.85 | BAZ2B (0.47) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL405018 | 0.85 | CREBBP (0.49) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL405109 | 0.84 | CREBBP (0.59) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL407838 | 0.84 | BAZ2B (0.46) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL407766 | 0.84 | BAZ2B (0.53) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL407478 | 0.83 | BAZ2B (0.46) | BAZ2BLMNAMAPTEP300CREBBP | |
| SCHEMBL10139772 | 0.83 | AURKA (0.62) | EP300CREBBPBRD4 | |
| SCHEMBL10139981 | 0.83 | CREBBP (0.63) | BAZ2BLMNAMAPTEP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | BAZ2B 506/4885LMNA 3834/4885MAPT 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.